Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Lentiviral-mediated COL7A1 Gene-modified Autologous Fibroblasts in Adults With Recessive Dystrophic Epidermolysis Bullosa.

NCT02493816 is registered in ClinicalTrials.gov with King's College London as lead sponsor.

NCT NCT02493816
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02493816 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Lentiviral-mediated COL7A1 Gene-modified Autologous Fibroblasts in Adults With Recessive Dystrophic Epidermolysis Bullosa.
Lead sponsor
King's College London
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2015
Completion date
March 31, 2018
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recessive dystrophic epidermolysis bullosa